Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
August 15, 2022 07:01 AM EDT
Bioregnum
R&D

Some­times you win. Some­times you lose. And some­times it's just an­oth­er PhI­II canakinum­ab fail

At this stage of the game, No­var­tis CEO Vas Narasimhan may be wish­ing he’d nev­er even heard of canakinum­ab.

Af­ter steer­ing the drug straight to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times